Modern scientific and clinical developments in the treatment of malignant neoplasms of the upper gastrointestinal tract: results of ASCO-2022

Abstract

Introduction. Malignant neoplasms of the upper gastrointestinal tract occupy the 6th position in terms of the frequency of detection of new cases of cancer. Within the framework of the Federal project “Fight against oncological diseases”, state tasks have been set that provide for a significant reduction in mortality from neoplasms, including malignant ones, to 185 cases per 100,000 people. The development, standardization and algorithmization of medical methodologies for drug treatment of cancer aimed at improving the quality of oncological care is underway. In early June 2022, the results of the latest clinical developments, including targeted and immune therapy for upper gastrointestinal tumors, were presented at the Annual Congress of the American Society of Clinical Oncology (ASCO). Popularization of innovative approaches to the treatment of cancerous tumors of the gastrointestinal tract fully meets the objectives of the Federal project.
 Materials and methods. This material was the result of a study of innovative clinical developments in drug therapy for tumors of the upper gastrointestinal tract, presented at the ASCO Annual Congress - June 2022 and the digital platform MEDTalks.nl: the Korean clinical trial K-Umbrella; the German-Swiss Phase 2b DANTE clinical trial; French national randomized trial GERCOR.
 Discussion and Conclusions. The results of the presented clinical developments demonstrate positive effects and an acceptable drug safety profile, which opens up prospects for their implementation in practice as part of innovative medical methodologies for the treatment of patients with malignant neoplasms of the upper gastrointestinal tract.